CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: Next, we analyzed the effects of the activated T cell secretome (with the same TCMs used in the experiment shown in Figure 1b) on the proliferation and apoptosis of untreated and imatinib-treated primary human CD34+ CML stem/progenitor cells.